FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308767515> ?p ?o ?g. }

• W4308767515 endingPage "12092" @default.
• W4308767515 startingPage "12077" @default.
• W4308767515 abstract "Aims: The proliferation and migration of vascular smooth muscle cells (VSMCs) play vital roles in the pathological process of neointima formation after vascular injury. Galangin, an extract of the ginger plant galangal, is involved in numerous biological activities, including inhibiting the proliferation and migration of tumor cells, but its effect on VSMCs is unknown. This study focused on the role and mechanism of galangin in the neointima formation induced by vascular injury. Methods and results: In this study, we found that galangin restrained the PDGF-BB-induced proliferation, migration and phenotypic switching of VSMCs in a concentration-dependent manner. In vivo, we established a model of carotid artery balloon injury in rats, followed by intragastric administration of galangin (40 mg kg-1 day-1 or 80 mg kg-1 day-1) for 14 or 28 consecutive days. Then, the degree of neointima hyperplasia was evaluated by H&E staining, and the level of relevant protein expression was assessed by immunofluorescence and western blotting. In vitro, we isolated and grew primary rat aortic smooth muscle cells, which were treated with PDGF-BB and different doses of galangin, and then CCK-8 assay, wound healing assay, transwell assay, western blotting and immunofluorescence assays were performed. We found that galangin significantly inhibited PDGF-BB-induced proliferation, migration, and phenotypic switching of VSMCs and promoted autophagy in VSMCs in vitro, and galangin significantly inhibited neointimal hyperplasia after the common carotid artery balloon injury in rats. In terms of mechanisms, galangin inhibited the PI3K/AKT/mTOR pathway, thereby suppressing VSMC's switch from a contractile to a synthetic phenotype, inhibiting VSMC proliferation, migration and phenotypic switching and upregulating the Beclin1 protein expression levels and the ratio of LC3BII/I, promoting VSMC autophagy, and thereby inhibiting neointimal hyperplasia after vascular injury. Conclusion: Our study suggests that galangin inhibits neointimal hyperplasia after vascular injury by inhibiting smooth muscle cell proliferation, migration and phenotypic switching and by promoting autophagy, and that galangin may be a promising drug for the prevention and treatment of vascular restenosis after PCI." @default.
• W4308767515 created "2022-11-15" @default.
• W4308767515 creator A5001636908 @default.
• W4308767515 creator A5003015705 @default.
• W4308767515 creator A5011524664 @default.
• W4308767515 creator A5019422491 @default.
• W4308767515 creator A5026582417 @default.
• W4308767515 creator A5037341172 @default.
• W4308767515 creator A5041971780 @default.
• W4308767515 creator A5075776410 @default.
• W4308767515 creator A5083377423 @default.
• W4308767515 date "2022-01-01" @default.
• W4308767515 modified "2023-09-25" @default.
• W4308767515 title "Galangin inhibits neointima formation induced by vascular injury <i>via</i> regulating the PI3K/AKT/mTOR pathway" @default.
• W4308767515 cites W116147156 @default.
• W4308767515 cites W1919941925 @default.
• W4308767515 cites W1974197340 @default.
• W4308767515 cites W1987430295 @default.
• W4308767515 cites W2044290370 @default.
• W4308767515 cites W2171239535 @default.
• W4308767515 cites W2171371398 @default.
• W4308767515 cites W2348693795 @default.
• W4308767515 cites W2383254385 @default.
• W4308767515 cites W2483085287 @default.
• W4308767515 cites W2551804260 @default.
• W4308767515 cites W2731446189 @default.
• W4308767515 cites W2740982903 @default.
• W4308767515 cites W2771809997 @default.
• W4308767515 cites W2799456798 @default.
• W4308767515 cites W2806217607 @default.
• W4308767515 cites W2905420415 @default.
• W4308767515 cites W2912587582 @default.
• W4308767515 cites W2964461736 @default.
• W4308767515 cites W2968830168 @default.
• W4308767515 cites W2975634197 @default.
• W4308767515 cites W2984608116 @default.
• W4308767515 cites W3005533031 @default.
• W4308767515 cites W3013608128 @default.
• W4308767515 cites W3082668623 @default.
• W4308767515 cites W3083341969 @default.
• W4308767515 cites W3086168133 @default.
• W4308767515 cites W3104632866 @default.
• W4308767515 cites W3106905870 @default.
• W4308767515 cites W3131505186 @default.
• W4308767515 cites W3158305827 @default.
• W4308767515 cites W3162006549 @default.
• W4308767515 cites W3165787945 @default.
• W4308767515 cites W3183229757 @default.
• W4308767515 cites W3198853168 @default.
• W4308767515 cites W4205376920 @default.
• W4308767515 cites W4225140280 @default.
• W4308767515 cites W4229442070 @default.
• W4308767515 cites W4285388758 @default.
• W4308767515 cites W4291227686 @default.
• W4308767515 doi "https://doi.org/10.1039/d2fo02441a" @default.
• W4308767515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36367287" @default.
• W4308767515 hasPublicationYear "2022" @default.
• W4308767515 type Work @default.
• W4308767515 citedByCount "2" @default.
• W4308767515 countsByYear W43087675152023 @default.
• W4308767515 crossrefType "journal-article" @default.
• W4308767515 hasAuthorship W4308767515A5001636908 @default.
• W4308767515 hasAuthorship W4308767515A5003015705 @default.
• W4308767515 hasAuthorship W4308767515A5011524664 @default.
• W4308767515 hasAuthorship W4308767515A5019422491 @default.
• W4308767515 hasAuthorship W4308767515A5026582417 @default.
• W4308767515 hasAuthorship W4308767515A5037341172 @default.
• W4308767515 hasAuthorship W4308767515A5041971780 @default.
• W4308767515 hasAuthorship W4308767515A5075776410 @default.
• W4308767515 hasAuthorship W4308767515A5083377423 @default.
• W4308767515 hasConcept C104317684 @default.
• W4308767515 hasConcept C126322002 @default.
• W4308767515 hasConcept C185592680 @default.
• W4308767515 hasConcept C2777302768 @default.
• W4308767515 hasConcept C2777339539 @default.
• W4308767515 hasConcept C2777810353 @default.
• W4308767515 hasConcept C2778004101 @default.
• W4308767515 hasConcept C2778095995 @default.
• W4308767515 hasConcept C2778283817 @default.
• W4308767515 hasConcept C2778583881 @default.
• W4308767515 hasConcept C2779395532 @default.
• W4308767515 hasConcept C2781011225 @default.
• W4308767515 hasConcept C2781263971 @default.
• W4308767515 hasConcept C2992686903 @default.
• W4308767515 hasConcept C55493867 @default.
• W4308767515 hasConcept C62478195 @default.
• W4308767515 hasConcept C71924100 @default.
• W4308767515 hasConcept C75217442 @default.
• W4308767515 hasConcept C85265743 @default.
• W4308767515 hasConcept C86554907 @default.
• W4308767515 hasConcept C86803240 @default.
• W4308767515 hasConcept C95444343 @default.
• W4308767515 hasConcept C98274493 @default.
• W4308767515 hasConceptScore W4308767515C104317684 @default.
• W4308767515 hasConceptScore W4308767515C126322002 @default.
• W4308767515 hasConceptScore W4308767515C185592680 @default.
• W4308767515 hasConceptScore W4308767515C2777302768 @default.
• W4308767515 hasConceptScore W4308767515C2777339539 @default.

• next